MedTrace Logo

Development of a Scientifically Informed Written Exposure Procedure (The SCRIPTS Study)

NCT03654625 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2020-03-16

No results posted yet for this study

Summary

Generalized anxiety disorder (GAD) is characterized by excessive and uncontrollable worry and anxiety. When people with GAD worry, they tend to think about problems and feared situations in a vague way. Preliminary research suggests that writing about feared situations in a structured and detailed fashion may help with worry. In this experiment, the investigators are looking to improve the writing intervention. The investigators are testing the immediate and short-term effects of a new writing intervention.

Conditions

  • Excessive Worry

Interventions

BEHAVIORAL

Standard Written Exposure

Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.

BEHAVIORAL

Enhanced Written Exposure

Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.

BEHAVIORAL

Control Condition

Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Ministry of Research, Innovation and Science, Ontario

    collaborator OTHER

  • Toronto Metropolitan University

    lead OTHER

Principal Investigators

  • Naomi Koerner, PhD · Toronto Metropolitan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-07
Primary Completion
2020-09-30
Completion
2020-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03654625 on ClinicalTrials.gov